224 related articles for article (PubMed ID: 31448902)
1. An Influenza Virus Entry Inhibitor Targets Class II PI3 Kinase and Synergizes with Oseltamivir.
O'Hanlon R; Leyva-Grado VH; Sourisseau M; Evans MJ; Shaw ML
ACS Infect Dis; 2019 Oct; 5(10):1779-1793. PubMed ID: 31448902
[TBL] [Abstract][Full Text] [Related]
2. Triple combination of amantadine, ribavirin, and oseltamivir is highly active and synergistic against drug resistant influenza virus strains in vitro.
Nguyen JT; Hoopes JD; Le MH; Smee DF; Patick AK; Faix DJ; Blair PJ; de Jong MD; Prichard MN; Went GT
PLoS One; 2010 Feb; 5(2):e9332. PubMed ID: 20179772
[TBL] [Abstract][Full Text] [Related]
3. In vitro activity of favipiravir and neuraminidase inhibitor combinations against oseltamivir-sensitive and oseltamivir-resistant pandemic influenza A (H1N1) virus.
Tarbet EB; Vollmer AH; Hurst BL; Barnard DL; Furuta Y; Smee DF
Arch Virol; 2014 Jun; 159(6):1279-91. PubMed ID: 24311151
[TBL] [Abstract][Full Text] [Related]
4. Reduction of Neuraminidase Activity Exacerbates Disease in 2009 Pandemic Influenza Virus-Infected Mice.
Ranadheera C; Hagan MW; Leung A; Collignon B; Cutts T; Theriault S; Embury-Hyatt C; Kobasa D
J Virol; 2016 Nov; 90(21):9931-9941. PubMed ID: 27558428
[TBL] [Abstract][Full Text] [Related]
5. Design, in silico studies, synthesis and in vitro evaluation of oseltamivir derivatives as inhibitors of neuraminidase from influenza A virus H1N1.
Neri-Bazán RM; García-Machorro J; Méndez-Luna D; Tolentino-López LE; Martínez-Ramos F; Padilla-Martínez II; Aguilar-Faisal L; Soriano-Ursúa MA; Trujillo-Ferrara JG; Fragoso-Vázquez MJ; Barrón BL; Correa-Basurto J
Eur J Med Chem; 2017 Mar; 128():154-167. PubMed ID: 28182988
[TBL] [Abstract][Full Text] [Related]
6. Oseltamivir-resistant influenza viruses isolated in South Korea from 2005 to 2010.
Cho HG; Choi JH; Lee HK; Mun SK; Lee JB; Jho EH; Kang C; Lim YH
Arch Virol; 2013 Nov; 158(11):2365-70. PubMed ID: 23690054
[TBL] [Abstract][Full Text] [Related]
7. Host-targeted nitazoxanide has a high barrier to resistance but does not reduce the emergence or proliferation of oseltamivir-resistant influenza viruses in vitro or in vivo when used in combination with oseltamivir.
Tilmanis D; Koszalka P; Barr IG; Rossignol JF; Mifsud E; Hurt AC
Antiviral Res; 2020 Aug; 180():104851. PubMed ID: 32544408
[TBL] [Abstract][Full Text] [Related]
8. Oseltamivir boosts 2009 H1N1 virus infectivity in vitro.
Lin X; Zhou J; Zhang Y; Wu J; Zhang F; Li Z; Zhang Y; Bi S; Shu Y; Wang Y
Biochem Biophys Res Commun; 2009 Dec; 390(4):1305-8. PubMed ID: 19879239
[TBL] [Abstract][Full Text] [Related]
9. Comprehensive assessment of 2009 pandemic influenza A (H1N1) virus drug susceptibility in vitro.
Gubareva LV; Trujillo AA; Okomo-Adhiambo M; Mishin VP; Deyde VM; Sleeman K; Nguyen HT; Sheu TG; Garten RJ; Shaw MW; Fry AM; Klimov AI
Antivir Ther; 2010; 15(8):1151-9. PubMed ID: 21149922
[TBL] [Abstract][Full Text] [Related]
10.
Lloren KKS; Kwon JJ; Choi WS; Jeong JH; Ahn SJ; Choi YK; Baek YH; Song MS
J Virol; 2019 Mar; 93(6):. PubMed ID: 30602610
[TBL] [Abstract][Full Text] [Related]
11. BPR2-D2 targeting viral ribonucleoprotein complex-associated function inhibits oseltamivir-resistant influenza viruses.
Shih SR; Horng JT; Poon LL; Chen TC; Yeh JY; Hsieh HP; Tseng SN; Chiang C; Li WL; Chao YS; Hsu JT
J Antimicrob Chemother; 2010 Jan; 65(1):63-71. PubMed ID: 19892833
[TBL] [Abstract][Full Text] [Related]
12. Chemical Genomics Approach Leads to the Identification of Hesperadin, an Aurora B Kinase Inhibitor, as a Broad-Spectrum Influenza Antiviral.
Hu Y; Zhang J; Musharrafieh R; Hau R; Ma C; Wang J
Int J Mol Sci; 2017 Sep; 18(9):. PubMed ID: 28885544
[TBL] [Abstract][Full Text] [Related]
13. Inhibition of influenza virus replication by plant-derived isoquercetin.
Kim Y; Narayanan S; Chang KO
Antiviral Res; 2010 Nov; 88(2):227-35. PubMed ID: 20826184
[TBL] [Abstract][Full Text] [Related]
14. Effect of aloin on viral neuraminidase and hemagglutinin-specific T cell immunity in acute influenza.
Huang CT; Hung CY; Hseih YC; Chang CS; Velu AB; He YC; Huang YL; Chen TA; Chen TC; Lin CY; Lin YC; Shih SR; Dutta A
Phytomedicine; 2019 Nov; 64():152904. PubMed ID: 31454654
[TBL] [Abstract][Full Text] [Related]
15. Influenza A(H1N1)pdm09 resistance and cross-decreased susceptibility to oseltamivir and zanamivir antiviral drugs.
Correia V; Santos LA; Gíria M; Almeida-Santos MM; Rebelo-de-Andrade H
J Med Virol; 2015 Jan; 87(1):45-56. PubMed ID: 25042157
[TBL] [Abstract][Full Text] [Related]
16. Antiviral activity of SA-2 against influenza A virus in vitro/vivo and its inhibition of RNA polymerase.
Yu J; Wang D; Jin J; Xu J; Li M; Wang H; Dou J; Zhou C
Antiviral Res; 2016 Mar; 127():68-78. PubMed ID: 26802558
[TBL] [Abstract][Full Text] [Related]
17. Neuraminidase Activity and Resistance of 2009 Pandemic H1N1 Influenza Virus to Antiviral Activity in Bronchoalveolar Fluid.
Ruangrung K; Suptawiwat O; Maneechotesuwan K; Boonarkart C; Chakritbudsabong W; Assawabhumi J; Bhattarakosol P; Uiprasertkul M; Puthavathana P; Wiriyarat W; Jongkaewwattana A; Auewarakul P
J Virol; 2016 May; 90(9):4637-4646. PubMed ID: 26912622
[TBL] [Abstract][Full Text] [Related]
18. Antivirals targeting the polymerase complex of influenza viruses.
Mifsud EJ; Hayden FG; Hurt AC
Antiviral Res; 2019 Sep; 169():104545. PubMed ID: 31247246
[TBL] [Abstract][Full Text] [Related]
19. Antivirals Targeting the Surface Glycoproteins of Influenza Virus: Mechanisms of Action and Resistance.
Bai Y; Jones JC; Wong SS; Zanin M
Viruses; 2021 Apr; 13(4):. PubMed ID: 33917376
[TBL] [Abstract][Full Text] [Related]
20. Triple combination of oseltamivir, amantadine, and ribavirin displays synergistic activity against multiple influenza virus strains in vitro.
Nguyen JT; Hoopes JD; Smee DF; Prichard MN; Driebe EM; Engelthaler DM; Le MH; Keim PS; Spence RP; Went GT
Antimicrob Agents Chemother; 2009 Oct; 53(10):4115-26. PubMed ID: 19620324
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
